Table 5 5ARI users stratified by eventual diagnosis
From: 5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
Overall cancers (n = 25) | No cancers (n = 29) | Clinically significant cancers (n = 17) | No Clinically significant cancers (n = 37) | |
|---|---|---|---|---|
Patients with prior negative biopsy | 7 (28.0%) | 14 (48.3%) | 7 (41.2%) | 14 (37.8%) |
PSA | 9.80 | 12.05 | 10.45 | 11.26 |
Corrected PSA | 19.6 | 24.1 | 20.9 | 22.52 |
PSA density | 0.228 | 0.164 | 0.254 | 0.166 |
Corrected PSA density | 0.456 | 0.329 | 0.507 | 0.332 |
Abnormal DRE | 6 (24.0%) | 7 (24.1%) | 4 (23.5%) | 9 (24.3%) |
PHI | 43.5 | 30.0 | 53.2 | 31.8 |
PHI density | 1.03 | 0.437 | 1.34 | 0.538 |